AVITA Medical, Inc. Stock price Australian S.E.

Equities

AVH

AU000000AVH4

Biotechnology & Medical Research

Market Closed - Australian S.E. 01:10:10 2024-03-28 am EDT 5-day change 1st Jan Change
4.95 AUD +0.61% Intraday chart for AVITA Medical, Inc. +2.27% +15.38%
Sales 2024 * 123M 80.01M Sales 2025 * 169M 110M Capitalization 633M 412M
Net income 2024 * -50M -32.56M Net income 2025 * -14M -9.12M EV / Sales 2024 * 5.24 x
Net Debt 2024 * 10.98M 7.15M Net Debt 2025 * 36.22M 23.59M EV / Sales 2025 * 3.95 x
P/E ratio 2024 *
-12.8 x
P/E ratio 2025 *
-81 x
Employees 207
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.93%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on AVITA Medical, Inc.

1 day+0.61%
1 week+2.27%
Current month-3.32%
1 month-9.67%
3 months+17.86%
6 months+9.51%
Current year+15.38%
More quotes
1 week
4.77
Extreme 4.77
5.06
1 month
4.77
Extreme 4.77
5.62
Current year
3.74
Extreme 3.74
5.62
1 year
2.88
Extreme 2.88
6.27
3 years
1.28
Extreme 1.28
6.27
5 years
1.28
Extreme 1.28
17.30
10 years
0.92
Extreme 0.92
17.30
More quotes
Date Price Change Volume
24-03-28 4.95 +0.61% 115,914
24-03-27 4.92 +3.14% 58,301
24-03-26 4.77 -1.24% 63,157
24-03-25 4.83 -3.01% 60,606
24-03-22 4.98 +2.89% 76,236

Delayed Quote Australian S.E., March 28, 2024 at 01:10 am EDT

More quotes
AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
24.57 AUD
Average target price
40.74 AUD
Spread / Average Target
+65.84%
Consensus
  1. Stock
  2. Equities
  3. Stock AVITA Medical, Inc.
  4. Stock AVITA Medical, Inc. - Australian S.E.